06915 江西生物
JIANGXI BIO
JIANGXI BIO
| Register Close | 2026/06/25 IPO Closing in 3 Days |
| Listing Date | 2026/06/30 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Jiangxi Institute of Biological Products Inc. is the largest provider and exporter of human tetanus antitoxins (‘‘Human TAT’’), in China. The Group existing products also include a number of veterinary pharmaceutical products, including veterinary tetanus antitoxin and PMSG, as well as certain hormonal pharmaceutical drugs designed to complement or support PMSG treatments.
--
According to the report, the Group is the largest Human TAT provider in China and globally in terms of sales volume in 2025, with a market share of 65.8% and 45.8%, respectively. The Group’s total sales volume of Human TAT in 2025 was 29.9 million units, with 13.5 million units sold in China and 16.4 million units exported to overseas markets.
--
As of December 31, 2025, the Group has established a comprehensive distribution network in China, spanning provincial, city, and county levels. This network ensures broad market coverage and efficient delivery of the Group’s products to over 27,000 medical institutions, including over 1,700 tertiary medical institutions in China.
--
The Group’s Human TAT, as included in Part A of the NRDL with full reimbursement coverage, the National Essential Drug List and National Emergency and Rescue Drugs Directory. Substantially all of the Group’s revenue was derived from the sales of Human TAT, its customers for Human TAT were distributors. End customers primarily comprised public hospitals, private hospitals, clinics and other medical institutions.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | Global |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 36.23M H shares |
| No. of International Offer Shares | 32.61M H shares |
| No. of HK Offer Shares | 3.62M H shares |
| Offer Price | $9.33 - $13.06 |
| Stock Code | 6915 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, China Merchants Securities (HK) Co., Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, China Merchants Securities (HK) Co., Limited, Futu Securities International (Hong Kong) Limited, Guosen Securities (HK) Brokerage Company, Limited, CMBC Securities Company Limited, Arta Asset Management Limited |
TIME TABLE
| Application Period | Jun 22 (Mon) - noon, Jun 25 (Thu) |
| Price Determination Date | Jun 26 (Fri) |
| Result Announcement Date | On or before Jun 29 (Mon) |
| Result Announcement Date | On or before Jun 29 (Mon) |
| Result Announcement Date | On or before Jun 30 (Tue) |
| Dealings in Shares commence on | Jun 30, 2026. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $9.33 - $13.06 |
| Capitalization | 2.88B - 4.03B |
| NAV / share ($) | $2.83 - $3.25 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 11.2, the net proceeds raised would be HKD 338.60M, of which |
| 33.7% : Research and development of product candidates |
| 31.4% : Construction and expansion of new facilities and production lines |
| 15.7% : Upgrades and optimization of technologies and processes |
| 10.3% : Reinforcement of sales and marketing capabilities |
| 8.8% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).